
A large study into rare blood clots linked with AstraZeneca Plc's (NASDAQ:AZN) COVID-19 vaccine found between one and three cases per million, and only after the first dose. The analysis sheds fresh light on the side effects of the shot.
A study published in the PLOS Medicine journal assessed health records of 46 million adults in England between December 2020 and March 2021 to assess the risk of clots in the month after vaccination with either the Pfizer Inc (NYSE:PFE) - BioNTech SE (NASDAQ:BNTX) vaccine or AstraZeneca-Oxford shot, compared with the unvaccinated.